We invest in passionate entrepreneurs with an ambition to impact the industry, who have an experienced team backed by academia and science.
We primarily invest in private companies. In addition, we invest selectively in public companies, and investment funds as a limited partner.
We invest predominantly in the drug development field, including related devices and services. This includes modalities such as cell and gene therapy, vaccines, biologics and small molecules.
Our evergreen structure allows long-term value creation in the portfolio. We invest off our own balance sheet and recycle the investment pool. We aim to be invested as long as we will contribute and build value.
Investments in the product development segment cover companies from formation and pre-clinical stage to clinical phase I/II/III. Investments in the commercial growth segment cover companies from early revenue-generation towards profitability.